unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Company profile
Ticker
UBX
Exchange
Website
CEO
Anirvan Ghosh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cenexys, Inc., Forge Inc
SEC CIK
UBX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
15 Apr 24
10-K
2023 FY
Annual report
15 Apr 24
8-K
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
15 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
20 Mar 24
EFFECT
Notice of effectiveness
11 Dec 23
424B3
Prospectus supplement
8 Dec 23
CORRESP
Correspondence with SEC
7 Dec 23
UPLOAD
Letter from SEC
7 Dec 23
S-3
Shelf registration
6 Dec 23
Latest ownership filings
4
Alexander Hieu Nguyen
27 Mar 24
SC 13G/A
Alyeska Investment Group, L.P.
14 Feb 24
4
Anirvan Ghosh
5 Feb 24
4
Anirvan Ghosh
31 Jan 24
4
Anirvan Ghosh
3 Nov 23
4
Anirvan Ghosh
31 Oct 23
4
Anirvan Ghosh
15 Sep 23
144
Notice of proposed sale of securities
15 Sep 23
4
Anirvan Ghosh
3 Aug 23
144
Notice of proposed sale of securities
3 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.77 mm | 8.77 mm | 8.77 mm | 8.77 mm | 8.77 mm | 8.77 mm |
Cash burn (monthly) | 3.75 mm | 1.27 mm | 4.98 mm | 4.29 mm | 2.37 mm | 3.32 mm |
Cash used (since last report) | 25.00 mm | 8.48 mm | 33.21 mm | 28.61 mm | 15.82 mm | 22.17 mm |
Cash remaining | -16.23 mm | 292.96 k | -24.43 mm | -19.84 mm | -7.05 mm | -13.40 mm |
Runway (months of cash) | -4.3 | 0.2 | -4.9 | -4.6 | -3.0 | -4.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 6 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 6.33 bn |
Total shares | 18.45 mm |
Total puts | 6.10 k |
Total calls | 1.40 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Arch Venture Fund VII | 10.05 mm | $14.67 mm |
Venrock Associates VII | 2.68 mm | $0.00 |
Mayo Foundation For Medical Education & Research | 1.57 mm | $25.56 mm |
WuXi PharmTech Healthcare Fund I | 1.48 mm | $24.03 mm |
Arch Venture | 1.00 mm | $2.41 bn |
Vanguard | 561.60 k | $1.35 bn |
Ubs Oconnor | 179.08 k | $429.79 mm |
Geode Capital Management | 131.78 k | $316.36 mm |
Mayo Clinic | 124.08 k | $297.79 mm |
BLK Blackrock | 113.46 k | $272.30 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | Alexander Hieu Nguyen | Common Stock, $0.0001 par value | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 25,104 |
26 Mar 24 | Alexander Hieu Nguyen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.62 | 30,000 | 48.60 k | 30,000 |
30 Jan 24 | Anirvan Ghosh | Common Stock, $0.0001 par value | Sell | Dispose S | No | Yes | 1.71 | 1,183 | 2.02 k | 79,426 |
2 Nov 23 | Anirvan Ghosh | Common Stock, $0.0001 par value | Sell | Dispose S | No | Yes | 1.83 | 589 | 1.08 k | 80,609 |
30 Oct 23 | Anirvan Ghosh | Common Stock, $0.0001 par value | Sell | Dispose S | No | Yes | 1.9 | 1,024 | 1.95 k | 81,198 |
14 Sep 23 | Anirvan Ghosh | Common Stock, $0.0001 par value | Sell | Dispose S | No | Yes | 2.47 | 1,246 | 3.08 k | 82,222 |
News
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
17 Apr 24
HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8
17 Apr 24
HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8
16 Apr 24
Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate
15 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
25 Mar 24